

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> <b>(PA 439.3)</b>	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
✓	AA	Alhaique, F., et al., "Cyclisation of dinitriles by sodium alkoxides a new synthesis of naphthyridines," <i>Tetrahedron Letters</i> , <b>1975</b> , 3, 173-174	
✓	AB	Ames, D.E., et al., "Condensation of $\beta$ -dicarbonyl compounds with halogenopyridinecarb-oxylic acids. A convenient synthesis of some naphthyridine derivatives," <i>J.C.S. Perkin I</i> , <b>1972</b> , 705-710	
✓	AC	Bodor, N., "Novel approaches in prodrug design," <i>Alfred Benzon Symposium</i> , <b>1982</b> , 17, 156-177	
✓	AD	Brooks, Peter C., et al., "Antiintegrin $\alpha\beta 3$ blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , <b>1995</b> , 96, 1815-1822	
*	AE	Bundgaard, H., <i>Design of Prodrugs</i> , <b>1985</b> , Elsevier, Amsterdam	
*	AF	Katritzky, A.R., et al. (Eds.), <i>Comprehensive Organic Functional Group Transformations</i> , Pergamon, <b>1995</b>	
✓	AG	Davies, S.G., et al., "Asymmetric synthesis of R- $\beta$ -amino butanoic acid and S- $\beta$ -tyrosine: homochiral lithium amide equivalents for Michael additions to $\alpha,\beta$ -unsaturated esters," <i>Tetra. Asymmetry</i> , <b>1991</b> , 2(3), 183-186	
✓	AH	Erle, D.J., et al., "Expression and function of the MadCAM-1 receptor, integrin $\alpha 4 \beta 7$ , on human leukocytes," <i>J. Immunol.</i> , <b>1994</b> , 153, 517-528	
*	AI	Encyclopedia of Reagents for Organic Synthesis, <i>John Wiley and Sons (eds.)</i> , <b>1995</b>	
✓	AJ	Giacomello, et al., "Synthesis of 2,6-naphthyridine," <i>Tetra. Letters</i> , <b>1965</b> , 16, 1117-1121	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> <b>(PA 439.3)</b>	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	AK	Green, T.W., et al., "Protective Groups in Organic Synthesis," <i>John Wiley and Sons (eds.)</i> , 1991	
✓	AL	Hammes, H., et al., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Medicine</i> , 1996, 2, 529-533	
✓	AM	Hodivala-Dilke, K.M., "β3-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival," <i>J. Clin. Invest.</i> , 1999, 103(2), 229-238	
✓	AN	Kalvin, D.M., et al., Synthesis of (4R)-D,L-[4- <sup>2</sup> H]- and (4S)-D,L-[4- <sup>2</sup> H] homoserine lactones," <i>J. Org. Chem.</i> , 1985, 50, 2259-2263	
✓	AO	Koivunen, E., et al., "Selection of peptides binding to the α <sub>5</sub> β <sub>1</sub> integrin from phage display library," <i>J. Biological Chemistry</i> , 1993, 268(27), 20205-20210	
✓	AP	Mitjans, F., et al., "An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," <i>J. Cell Science</i> , 1995, 108, 2825-2838	
✓	AQ	Molina, P., et al., "Iminophosphorane-mediated annelation of a pyridine ring into a preformed pyridine one: synthesis of naphthyridine, pyrido [1,2-c] pyrimidine and pyrido [1,2-c] quinazoline derivatives," <i>Tetrahedron</i> , 1992, 48(22), 4601-4616	
✓	AR	Newham, P., et al., "Integrin adhesion receptors: structure, function and implications for biomedicine," <i>Molecular Medicine Today</i> , 1996, 304-313	
✓	AS	Numata, A., et al., "General synthetic method for naphthyridines and their N-oxides containing isoquinolinic nitrogen," <i>Synthesis</i> , 1999, 2, 306-311	
✓	AT	Sakamoto, T., et al., "Condensed heteroaromatic ring systems. III. synthesis of naphthyridine derivatives by cyclization of ethynylpyridinecarboxamides," <i>Chem. Pharm. Bull.</i> 1985, 33(2), 626-633	
EXAMINER		DATE CONSIDERED	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> (PA 439.3)	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
✓	<b>AU</b>	Singh, G., et al., "Prodrug approach in new drug design and development," <i>J. Sci. Ind. Res.</i> , <b>1996</b> , <i>55</i> , 497-510	
✓	<b>AV</b>	Srivatsa, S.S., et al., "Selective $\alpha\beta_3$ integrin blockade potentially limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin $\alpha\beta_3$ and osteopontin expression during neointima formation," <i>Cardiovascular Research</i> , <b>1997</b> , <i>36</i> , 408-428	
✓	<b>AW</b>	Stupack, D.G., et al., "induction of $\alpha\beta_3$ integrin-mediated attachment to extracellular matrix in $\beta_1$ integrin (CD29)-negative B cell lines," <i>Experi. Cell Research</i> , <b>1992</b> , <i>203</i> , 443-448	
✓	<b>AX</b>	Tan R., et al., "Synthesis of 2, 6-naphthyridine and some of its derivatives," <i>Tetrahedron Letters</i> , <b>1965</b> , <i>31</i> , 2737-2744	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	